Across TCGA pan-cancer cohorts, BRINP2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated BRINP2 data layer compared with 24 for mass-spec protein and 10 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher BRINP2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BRINP2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
GBM are the cancer types where BRINP2 mass-spec protein most reproducibly stratifies survival.